Searches for KLOW have grown fivefold in a year, and the fastest-rising question attached to it is "klow peptide dosage and frequency chart." That tells you two things. A lot of people are buying a four-peptide blend, and a lot of them are working out how to dose it after the vial has arrived.
KLOW is not a peptide. It is a product name for four peptides in one vial: GHK-Cu, BPC-157, TB-500, and KPV. Each of those has its own evidence record, and the blend has none. So what is actually in it, what has each part been shown to do, and what does a fixed ratio do to your dosing? Let's dive in.
TLDR
What is KLOW? A vendor-named blend, most commonly 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV in an 80 mg vial. Ratios vary by seller. GLOW is the same thing without the KPV.
Evidence: No study of the blend exists. Of the four components, only GHK-Cu has controlled human trials (three, mixed, all topical). BPC-157's human record is two people. TB-500 borrows its evidence from the full-length parent protein. KPV has never been given to a human being in any study.
Dosage: There is no validated protocol. Because the ratio is fixed, dosing for one component sets the dose of the other three. At the common 4 mL reconstitution, every 10 units delivers 1.25 mg GHK-Cu and 250 mcg each of the rest.
Safety: Four unknown safety profiles plus an untested interaction. A full 80 mg vial carries roughly 8 mg of elemental copper. TB-500 is contraindicated in anyone with active or suspected cancer. KPV has no toxicology data of any kind.
Legal Status (September 2026): None of the four is approved. In July 2026 an FDA advisory committee recommended BPC-157, TB-500, and KPV for compounding, against FDA staff advice; nothing has been added to the bulks list. BPC-157 and TB-500 are WADA-prohibited.
What Is KLOW, Exactly?
Let's get this straight first. KLOW has no inventor, no paper, and no molecule. It is a name that research-use-only vendors put on a lyophilized mix of four separately made peptides, and the name has stuck because it's easier to search for than "GHK-Cu BPC-157 TB-500 KPV blend."
| Component | What it is | Typical amount per vial |
|---|---|---|
| GHK-Cu | Copper-binding tripeptide found in human plasma | 50 mg |
| BPC-157 | 15-amino-acid fragment of a gastric protein | 10 mg |
| TB-500 | 7-amino-acid fragment of thymosin beta-4 | 10 mg |
| KPV | 3-amino-acid tail of alpha-MSH | 10 mg |
That 50/10/10/10 split is the most common listing, but it is not a standard. Some sellers offer 5/5/10/5 under a different name. Check the actual milligrams on the vial you have, because every dosing number below depends on them.
By weight, KLOW is mostly GHK-Cu. Five-eighths of the vial is a copper peptide with cosmetic-grade evidence, and the three "healing" peptides people buy it for make up the rest.
Why Do Blends Exist?
Not because anyone showed the four work better together. Nobody has looked.
Blends exist for commercial reasons that are worth understanding, because they explain the product. One vial is one SKU, one price, one checkout. It removes the reconstitution and syringe math for four separate vials, which is a real convenience. And it lets a seller describe "synergy" between structural repair, cell migration, collagen signalling, and inflammation control, which sounds like a mechanism and is actually a list of four marketing claims placed side by side.
The cost of that convenience is the fixed ratio. You cannot raise the BPC-157 without raising the copper. You cannot drop the TB-500 if you have a reason to avoid angiogenic compounds. You cannot run the KPV on its own to see whether it does anything for you. Everything moves together, and the ratio was chosen by whoever priced the vial.
What Each Component Has Actually Been Shown to Do
This is where the article earns its keep, because the blend's reputation is borrowed from four separate evidence records that are nothing like each other.
GHK-Cu
The only one of the four with controlled human trials, and they are mixed. The largest, in 86 patients with venous leg ulcers, found no difference between GHK-Cu cream and placebo (Bishop et al., 1992, Journal of Vascular Surgery, PMID 1495150). A 13-patient trial after laser resurfacing found no objective improvement, only higher patient-reported satisfaction (Miller et al., 2006, Archives of Facial Plastic Surgery, PMID 16847171). A 40-woman trial of a nanocarrier serum did report reduced wrinkle depth and volume.
Every one of those was topical. There is no controlled human trial of injected GHK-Cu, which is how it is delivered in KLOW. The 1980 founding paper in Nature described its effects in culture as ranging from growth stimulation "to outright toxicity" (Pickart et al., 1980, Nature, PMID 7453802), and a 1982 study found that three chemically unrelated copper carriers all induced blood-vessel growth, but only when bound to copper (Raju et al., 1982, JNCI, PMID 6182332). Whether the peptide or the copper is doing the work is still not settled.
BPC-157
Hundreds of animal studies from one research group, and a human record that consists of two healthy adults given intravenous doses in a 2025 pilot with no controls (Lee and Burgess, 2025, Alternative Therapies in Health and Medicine, PMID 40131143). A 2026 primer for sports physicians put it plainly: indications, dosing, frequency, and duration of treatment remain unknown (Mayfield et al., 2026, American Journal of Sports Medicine, PMID 41476424). The 250 to 500 mcg daily figures everyone uses come from animal extrapolation and community practice, and we've laid out where every one of them comes from in our BPC-157 dosage guide.
TB-500
The trap here is that almost all the human research, including the Phase 3 eye-drop trial and the cardiac pilot (Zhu et al., 2016, Cytotherapy, PMID 27288307), tested full-length thymosin beta-4, not the seven-amino-acid fragment sold as TB-500. A 2024 study also showed TB-500 is rapidly broken down into a smaller metabolite, Ac-LKKTE, which retained activity in the experimental models (Rahaman et al., 2024, Journal of Chromatography B, PMID 38382158). The fragment's own human evidence is close to zero. Full breakdown in our TB-500 vs thymosin beta-4 article.
KPV
A real anti-inflammatory signal in cells and mice. KPV inhibited NF-κB signalling in human gut cells and reduced chemically induced colitis in mice when given in drinking water (Dalmasso et al., 2008, Gastroenterology, PMID 18061177), and injected KPV reduced skin inflammation in a 1994 mouse study (Macaluso et al., 1994, Journal of Neuroscience, PMID 8158274).
And then nothing. When the FDA reviewed KPV for its July 2026 advisory committee, the agency searched the literature and reported that it had not identified any clinical studies or human exposure data for KPV by any route of administration. No trial is registered anywhere. Its molecular target is unknown. It is three amino acids from a hormone every person makes, which is a reason to expect low toxicity, but it is not a measurement of it.
| Component | Best human evidence | Injected in humans, controlled? | ONPEPS grade |
|---|---|---|---|
| GHK-Cu | Three topical RCTs, mixed results | No | C |
| BPC-157 | Two-person IV safety pilot | No | C |
| TB-500 | Borrowed from full-length Tβ4 | No | D |
| KPV | None. Zero human studies. | No | D |
| KLOW blend | None | No | — |
Put four compounds with thin evidence in one vial and you don't get a compound with strong evidence. You get four thin records and a fifth unknown: what they do to each other.
The Fixed-Ratio Problem: KLOW Dosing Math
Here's the part behind the "dosage chart" searches. There is no validated chart, but there is arithmetic, and it's worth doing carefully because the blend makes it unusual.
Start with the vial. At 50/10/10/10, the concentration of each component depends on how much bacteriostatic water you add.
| BAC water added | Per 10 units (0.1 mL) | Per 20 units (0.2 mL) |
|---|---|---|
| 2 mL | 2.5 mg GHK-Cu · 500 mcg BPC-157 · 500 mcg TB-500 · 500 mcg KPV | 5 mg GHK-Cu · 1 mg each of the others |
| 4 mL | 1.25 mg GHK-Cu · 250 mcg BPC-157 · 250 mcg TB-500 · 250 mcg KPV | 2.5 mg GHK-Cu · 500 mcg each of the others |
| 8 mL | 0.625 mg GHK-Cu · 125 mcg each of the others | 1.25 mg GHK-Cu · 250 mcg each of the others |
Now the problem. Say you want to dose the way the BPC-157 community does, at 250 mcg twice a day. At 4 mL that is 10 units, twice daily. Fine. But look at what rides along:
Your TB-500 becomes 500 mcg per day, which is 3.5 mg per week, delivered daily instead of in the twice-weekly 2 to 2.5 mg shots that TB-500 protocols use. Your GHK-Cu becomes 2.5 mg per day, injected, in a compound whose only human trials were creams. Your KPV becomes 500 mcg per day of a peptide with no human dose ever tested.
Or dose it the other way. If you decide 1 mg of injected GHK-Cu a day is enough copper, you're at 8 units at 4 mL, and your BPC-157 drops to 200 mcg a day, below what most protocols use.
Whatever you pick, you are choosing a dose for one peptide and accepting whatever that implies for the other three. That is the fixed-ratio problem, and no chart fixes it.
Run your own numbers with the reconstitution calculator and the dosage calculator, entering each component separately. And treat the vial as a multi-dose sterile vial: discard 28 days after first puncture, new needle every draw.
What the Community Reports
Reported protocols cluster around 10 to 20 units daily at a 4 mL reconstitution, usually subcutaneous near the injury or in the abdomen, for four to eight weeks, then a break. Some people split it morning and evening because of BPC-157's short half-life. Almost nobody adjusts for the fact that the TB-500 and GHK-Cu don't need daily dosing at all.
Reported effects are what you'd expect from a BPC-157 and TB-500 combination: people describe less joint and tendon pain over weeks three to six, and some describe skin and hair changes they attribute to the copper. None of this is controlled, and a blend makes it impossible to say which component did what. That is a description of what people are doing, not a recommendation.
Side Effects and Safety
The copper load
GHK-Cu is about 16% copper by weight, so a 50 mg vial carries roughly 8 mg of elemental copper. Spread over a four-week cycle that is a modest amount next to the 10 mg per day oral upper limit for adults. But injected copper bypasses the gut, which is where the body regulates how much copper it absorbs, and no human study has measured what weeks of subcutaneous copper peptide do to copper status. The rodent data showing dose-dependent immunosuppression and liver changes used copper-free GHK, so it doesn't map cleanly either. Unknown, not reassuring.
TB-500 and angiogenesis
TB-500 promotes new blood-vessel growth, which is the mechanism behind its benefits and exactly why it is not appropriate for anyone with active or suspected cancer. Tβ4 expression is elevated in several cancer types in preclinical models (Xing et al., 2021, Frontiers in Endocrinology), though which way the causation runs is unclear. Full discussion in our TB-500 side effects article. In a blend you can't leave it out.
BPC-157
Injection-site reactions, occasional nausea, headache, and dizziness at higher doses are what the community reports. Nothing from controlled human data, because there isn't any.
KPV
No human safety data by any route. The FDA found no repeat-dose, genotoxicity, reproductive, or carcinogenicity studies either. The one safety argument the FDA noted for KPV was that it penetrates skin poorly, which limits systemic exposure from the topical cream that was nominated. Injecting it removes that argument.
The interaction nobody has tested
Four peptides, one syringe, and zero studies of what happens when they are given together. GHK-Cu and TB-500 are both angiogenic. BPC-157 modulates VEGF and nitric oxide. Stacking three pro-angiogenic signals is a plausible reason for caution in anyone with a tumour history, and it is also a plausible reason the blend "works" for tendons. Both can be true. Neither has been measured.
Product quality
A single-peptide vial can be identity-tested with mass spectrometry against one expected mass. A four-peptide vial needs four identities confirmed and four quantities measured, and a certificate of analysis that reports "99% purity" for the blend tells you almost nothing about whether the ratio on the label is the ratio in the powder. Ask what was tested, by which lab, for which batch. If the answer is one purity number, that is not a test of a blend.
KLOW vs GLOW vs the Wolverine Stack
| Name | Contents | Typical vial | What's different |
|---|---|---|---|
| Wolverine stack | BPC-157 + TB-500 | Two separate vials, or 10 + 10 mg | Adjustable ratio; the original recovery pairing |
| GLOW | GHK-Cu + BPC-157 + TB-500 | 70 mg (50/10/10) | Adds copper peptide for skin and collagen |
| KLOW | GHK-Cu + BPC-157 + TB-500 + KPV | 80 mg (50/10/10/10) | Adds KPV for "inflammation" |
The honest comparison is that GLOW and KLOW are the Wolverine stack with copper on top, and KLOW adds a tripeptide that has never been studied in a person. If you want the two peptides with the most evidence for recovery, the Wolverine stack gives you them in a ratio you control. We compared the mechanisms in our TB-500 vs BPC-157 article.
Legal Status
None of the four components is approved for human use anywhere. Three of them were before the FDA's Pharmacy Compounding Advisory Committee on July 23, 2026: BPC-157 (for ulcerative colitis), TB-500 (for wound healing), and KPV (for wound healing and inflammatory conditions). The committee recommended all three for the 503A bulks list by 8 to 6 votes, against the recommendation of the FDA's own scientists, who found insufficient human evidence for every substance reviewed. The votes are advisory, nothing has been added to the list, and no US pharmacy has a lawful basis to compound any of them today. Our July 2026 FDA update has the full record.
GHK-Cu was on a separate track. The nomination for injectable GHK-Cu was withdrawn; only the non-injectable form remains under review, with a committee date expected before the end of February 2027. The injectable form in KLOW is therefore not before the committee at all.
For athletes: BPC-157 and TB-500 are on the 2026 WADA Prohibited List. GHK-Cu and KPV are not named. A blend that contains prohibited substances is a prohibited blend.
The Honest Take
KLOW is a convenient way to buy four research peptides at once, and the two that people actually feel, BPC-157 and TB-500, are the same two they would feel from the Wolverine stack. The copper adds a skin-and-collagen story with topical-only evidence and an injected copper load nobody has studied. The KPV adds a name to the label.
The blend's real cost isn't the price. It's that it takes the one thing you could control, the dose of each peptide, and locks it to a ratio a vendor chose.
If you're going to use these compounds, the case for buying them separately is stronger than the case for buying them mixed. If you already have the vial, do the arithmetic for each component before you draw the first dose, and know that the number you land on is a choice, not a protocol.
FAQ
What is KLOW peptide?
A vendor-named blend of four peptides: GHK-Cu, BPC-157, TB-500, and KPV, most commonly 50/10/10/10 mg in an 80 mg vial. It is not a single compound and has no study of its own.
What is KLOW peptide used for?
Community use is injury and tendon recovery, gut inflammation, and skin. Those uses are borrowed from the individual components, none of which has a validated human indication.
What is the difference between KLOW and GLOW?
KPV. GLOW is GHK-Cu + BPC-157 + TB-500 (70 mg). KLOW adds 10 mg of KPV (80 mg).
How do you reconstitute an 80 mg KLOW vial?
Commonly with 4 mL of bacteriostatic water, which gives 1.25 mg GHK-Cu and 250 mcg each of BPC-157, TB-500, and KPV per 10 units. Use the reconstitution calculator for your own vial.
What is the KLOW dosage?
There is no validated dose. Reported community protocols are 10 to 20 units daily at a 4 mL reconstitution, for four to eight weeks. Because the ratio is fixed, that sets all four doses at once.
How much copper is in KLOW?
Roughly 8 mg of elemental copper in a 50 mg GHK-Cu vial. Injected copper bypasses the gut's regulation, and no human study has measured the effect of weeks of subcutaneous copper peptide.
Does KLOW have side effects?
Injection-site reactions are the most reported. The real concerns are theoretical: an untested four-way interaction, three pro-angiogenic components, and one component with no human safety data at all.
Is KLOW safe for someone with a history of cancer?
TB-500 is not appropriate for anyone with active or suspected cancer because of its angiogenic mechanism, and the blend cannot be used without it.
Is KLOW legal?
None of the four components is approved for human use. It is sold as a research chemical. The July 2026 FDA advisory vote did not change that.
Is KLOW banned by WADA?
Yes in practice. BPC-157 and TB-500 are on the 2026 Prohibited List, so any blend containing them is prohibited for tested athletes.
Is KLOW better than the Wolverine stack?
Nobody has compared them. KLOW is the Wolverine stack plus copper and KPV, at a ratio you can't adjust. Buying the components separately gives you the same two active peptides with control over the dose.
Resources
Bishop et al. (1992), Journal of Vascular Surgery, GHK-Cu venous ulcer RCT — https://pubmed.ncbi.nlm.nih.gov/1495150/
Miller et al. (2006), Archives of Facial Plastic Surgery, GHK-Cu after laser resurfacing — https://pubmed.ncbi.nlm.nih.gov/16847171/
Pickart et al. (1980), Nature, the GHK founding paper — https://pubmed.ncbi.nlm.nih.gov/7453802/
Raju et al. (1982), JNCI, copper carriers and angiogenesis — https://pubmed.ncbi.nlm.nih.gov/6182332/
Li et al. (2015), Pharmaceutical Research, GHK-Cu skin penetration — https://pubmed.ncbi.nlm.nih.gov/25690343/
Lee and Burgess (2025), Alternative Therapies in Health and Medicine, BPC-157 IV pilot — https://pubmed.ncbi.nlm.nih.gov/40131143/
Mayfield et al. (2026), American Journal of Sports Medicine, injectable peptide primer — https://pubmed.ncbi.nlm.nih.gov/41476424/
He et al. (2022), BPC-157 review — https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
Rahaman et al. (2024), Journal of Chromatography B, TB-500 metabolites — https://pubmed.ncbi.nlm.nih.gov/38382158/
Zhu et al. (2016), Cytotherapy, Tβ4 cardiac pilot — https://pubmed.ncbi.nlm.nih.gov/27288307/
Xing et al. (2021), Frontiers in Endocrinology, Tβ4 in cancer — https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/
Dalmasso et al. (2008), Gastroenterology, KPV and intestinal inflammation — https://pubmed.ncbi.nlm.nih.gov/18061177/
Macaluso et al. (1994), Journal of Neuroscience, alpha-MSH peptides and inflammation — https://pubmed.ncbi.nlm.nih.gov/8158274/
Luger and Brzoska (2007), Annals of the Rheumatic Diseases, alpha-MSH related peptides — https://pubmed.ncbi.nlm.nih.gov/17934097/
FDA, Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026 — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
FDA, bulk drug substances that may present significant safety risks (Category 2) — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
WADA 2026 Prohibited List — https://www.wada-ama.org/en/resources/2026-prohibited-list
